| | 161814-49-9 Basic information More.. |
| Product Name: | AMPRENAVIR | | Synonyms: | KVX-478;AGENERASE;AMPRENAVIR;141W94;PROZEI;141W94, KVX-478, Agenerase, Prozei,;Carbamic acid, (1S,2R)-3-(4-aminophenyl)sulfonyl(2-methylpropyl)amino-2-hydroxy-1-(phenylmethyl)propyl-, (3S)-tetrahydro-3-furanyl ester;Angenerase | | CAS: | 161814-49-9 | | MF: | C25H35N3O6S | | MW: | 505.63 | | EINECS: | 827-179-5 | | Mol File: | 161814-49-9.mol |  |
Use
Amprenavir was launched as Agenerase in the US for the treatment of
AIDS patients in combination with approved agent antiretroviral nucleoside
analogs. It is the fifth non-peptidic inhibitor of HIV-1 protease to be marketed in
this indication after the last approved Neflinavir. Amprenavir, designed via a
structure-based process, is the smallest molecule in the 《navir》 class and
exhibits a reduced peptidic character. An improved process for preparation
comprising four steps from a (1S, 2R)-2-hydroxy-3-aminopropylcarbamate has
been developed. Amprenavir is a potent inhibitor of HIV-1 aspartyl protease (Ki
= 0.6nM), an enzyme required by the virus to cleave pro-form polyproteins to
structural proteins during the last stage in the replication process. The
compound displays good oral bioavailability in humans and penetrates the CNS,
which is an important advantage in long-term treatment. Its plasma half-life is
approximately 10h. Treatment with Amprenavir in combination with nucleoside
analog reverse transcriptase inhibitors considerably decreases viral load and
restores CD4+ T-cell counts in patients with HIV infection.
- AMPRENAVIR
-
- US $10.00-200.00 / G
- 2022-11-05
- CAS:161814-49-9
- Min. Order: 100G
- Purity: 99.99%
- Supply Ability: 20MT
- Amprenavir
-
- US $0.00 / KG
- 2022-02-09
- CAS:161814-49-9
- Min. Order: 1KG
- Purity: 98.1%
- Supply Ability: 100 tons
- Amprenavir
-
- US $15.00-10.00 / KG
- 2021-07-13
- CAS:161814-49-9
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Supply Ability: Monthly supply of 1 ton
|
|
161814-49-9
Recommend Suppliers |
|